Adjuvant treatments for triple-negative breast cancers von Joensuu, H, Gligorov, J

Volltext

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer von Gennari, A., André, F., Barrios, C.H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., Gligorov, J., Hurvitz, S.A., Im, S.-A., Krug, D., Kunz, W.G., Loi, S., Penault-Llorca, F., Ricke, J., Robson, M., Rugo, H.S., Saura, C., Schmid, P., Singer, C.F., Spanic, T., Tolaney, S.M., Turner, N.C., Curigliano, G., Loibl, S., Paluch-Shimon, S., Harbeck, N.

Volltext

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) von Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., André, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M.-J., Carey, L.A., Cortés, J., El Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S.-B., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., Winer, E.P.

Volltext

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally adv... von Miles, D., Gligorov, J., Cameron, D., Xu, B., Semiglazov, V., Reinisch, M., Patre, M., Morales, L., Patel, S.L., Barata, T., Xu, B., Shao, Z., Wang, X., Geng, C., Yan, X., Tong, Z., Sun, T., Yang, J., Liu, Q., Zhang, S., De Laurentiis, M., Santoro, A., Colleoni, M., Cortesi, L., Placido, S., Ferrau, F., Del Mastro, L., Tonini, G., Montemurro, F., Bianchi, G., Prete, S., Allegrini, G., Naso, G., Vici, P., Loirat, D., Tredan, O., Gligorov, J., Timar David, M., Dohollou, N., Spano, J.-P., Mansi, L., Andrade, L., Damian, F., Aleixo, S., Junior, R., Reinisch, M., Grischke, E.-M., Harbeck, N., Peters, U., Fischer, D., Forstbauer, H., Warner, E., Bouganim, N., Vandenberg, T., Pavic, M., Robinson, A., Califaretti, N., Alacacioglu, A., Gumus, M., Yalcin, B., Cicin, I., Kose, F., Cubukcu, E., Wardley, A., Miles, D., Gupta, S., Mohapatra, P., Ghadyalpatil, N., Singhal, M., Agarwal, A., Wolf, I., Gal Yam, E., Yerushalmi, R., Peretz, T., Ben Baruch, N., Hamilton, E., Brufsky, A., Wright, G., Graff, S., Semiglazov, V., Ruiz Borrego, M., Merino, L., Guerra Martinez, J., Ohtani, S., Inoue, K., Ito, Y., Niikura, N., Sagara, Y., Yanagita, Y., Kaen, D., Nervo, A., Melichar, B., Sormova, P., Sufliarsky, J., Kakalejcik, M., Belbaraka, R., Errihani, H., Le Than, D., Pham, D., Papandreou, C.

Volltext

St Gallen International Consensus Guidelines in early breast cancer: experts to prevent patients’ overtreatment and breaking the bank? von Arnedos, M., Gligorov, J.

Volltext

High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers von Palich, R., Veyri, M., Vozy, A., Marot, S., Gligorov, J., Benderra, M.-A., Maingon, P., Morand-Joubert, L., Adjoutah, Z., Marcelin, A.-G., Spano, J.-P., Barrière, J.

Volltext

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) von Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C.H., Bergh, J., Biganzoli, L., Blackwell, K.L., Cardoso, M.J., Cufer, T., El Saghir, N., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Giordano, S.H., Gligorov, J., Goldhirsch, A., Harbeck, N., Houssami, N., Hudis, C., Kaufman, B., Krop, I., Kyriakides, S., Lin, U.N., Mayer, M., Merjaver, S.D., Nordström, E.B., Pagani, O., Partridge, A., Penault-Llorca, F., Piccart, M.J., Rugo, H., Sledge, G., Thomssen, C., van't Veer, L., Vorobiof, D., Vrieling, C., West, N., Xu, B., Winer, E.

Volltext

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer tr... von Gourgou-Bourgade, S., Cameron, D., Poortmans, P., Asselain, B., Azria, D., Cardoso, F., A'Hern, R., Bliss, J., Bogaerts, J., Bonnefoi, H., Brain, E., Cardoso, M.J., Chibaudel, B., Coleman, R., Cufer, T., Dal Lago, L., Dalenc, F., De Azambuja, E., Debled, M., Delaloge, S., Filleron, T., Gligorov, J., Gutowski, M., Jacot, W., Kirkove, C., MacGrogan, G., Michiels, S., Negreiros, I., Offersen, B.V., Penault Llorca, F., Pruneri, G., Roche, H., Russell, N.S., Schmitt, F., Servent, V., Thürlimann, B., Untch, M., van der Hage, J.A., van Tienhoven, G., Wildiers, H., Yarnold, J., Bonnetain, F., Mathoulin-Pélissier, S., Bellera, C., Dabakuyo-Yonli, T.S.

Volltext

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (B... von Pierga, J.-Y., Bidard, F.-C., Autret, A., Petit, T., Andre, F., Dalenc, F., Levy, C., Ferrero, J.-M., Romieu, G., Bonneterre, J., Lerebours, F., Bachelot, T., Kerbrat, P., Campone, M., Eymard, J.-C., Mouret-Reynier, M.-A., Gligorov, J., Hardy-Bessard, A.-C., Lortholary, A., Soulie, P., Boher, J.-M., Proudhon, C., Charafe-Jaufret, E., Lemonnier, J., Bertucci, F., Viens, P.

Volltext

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) von Cardoso, F, Costa, A, Norton, L, Senkus, E, Aapro, M, André, F, Barrios, C.H, Bergh, J, Biganzoli, L, Blackwell, K.L, Cardoso, M.J, Cufer, T, El Saghir, N, Fallowfield, L, Fenech, D, Francis, P, Gelmon, K, Giordano, S.H, Gligorov, J, Goldhirsch, A, Harbeck, N, Houssami, N, Hudis, C, Kaufman, B, Krop, I, Kyriakides, S, Lin, U.N, Mayer, M, Merjaver, S.D, Nordström, E.B, Pagani, O, Partridge, A, Penault-Llorca, F, Piccart, M.J, Rugo, H, Sledge, G, Thomssen, C, van’t Veer, L, Vorobiof, D, Vrieling, C, West, N, Xu, B, Winer, E

Volltext

Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program von Bello Roufai, D., Gonçalves, A., De La Motte Rouge, T., Akla, S., Blonz, C., Grenier, J., Gligorov, J., Saghatchian, M., Bailleux, C., Simon, H., Desmoulins, I., Tharin, Z., Renaud, E., Bertho, M., Benderra, M-A, Delaloge, S., Robert, L., Cottu, P., Pierga, J. Y., Loirat, D., Bertucci, A., Renouf, B., Bidard, F. C., Lerebours, F.

Volltext

Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two... von Pivot, X., Verma, S., Fallowfield, L., Müller, V., Lichinitser, M., Jenkins, V., Sánchez Muñoz, A., Machackova, Z., Osborne, S., Gligorov, J.

Volltext

Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study von Pivot, X., Spano, J.P., Espie, M., Cottu, P., Jouannaud, C., Pottier, V., Moreau, L., Extra, J.M., Lortholary, A., Rivera, P., Spaeth, D., Attar-Rabia, H., Benkanoun, C., Dima-Martinez, L., Esposito, N., Gligorov, J.

Volltext

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 p... von Pivot, X., Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L., Fallowfield, Lesley, Jenkins, Valerie, Kilkerr, Justine, Langridge, Carolyn, Monson, Kathryn, Jakobsen, Erik Hugger, Nielsen, Mette Holck, Linnet, Soeren, Knoop, Ann, Pivot, Xavier, Bonnefoi, Herve, Mousseau, Mireille, Zelek, Laurent, Bourgeois, Hugues, Lefeuvre, Claudia Plesse, Bachelot, Thomas, Petit, Thierry, Brain, Etienne, Levy, Christelle, Gligorov, Joseph, Augustin, Doris, Graf, Heiko, Heinrich, Georg, Kroening, Hendrik, Kuemmel, Sherko, Müller, Volkmar, Overkamp, Friedrich, Park-Simon, Tjoung-Won, Schmidt, Marcus, Perlova-Griff, Lidia, Wolf, Christopher, Colleoni, Marco, Ballestrero, Alberto, Bernardo, Antonio, Ribecco, Angela Stefania, Gianni, Luca, Curigliano, Giuseppe, Brewczynska, Elżbieta, Jassem, Jacek, Shirinkin, Vadim, Manikhas, Alexey, Dvornichenko, Victoria, Lichinitser, Mikhail, Semiglazov, Vladimir, Mukhametshina, Guzel, Bulavina, Irina, Arranz, Enrique Espinosa, Ocon, Francisco Carabantes, Vivanco, Guillermo López, Bofill, Javier Salvador, Quintela, Ignacio Porras, Muñoz, Alfonso Sanchez, Pérez, Yolanda Fernández, Espinosa, Javier Cassinello, Alvarez, José Valero, del Prado, Rodrigo Lastra, De Merino, LuisLa Cruz, García, José Manuel Pérez, Frances, Santos Enrech, Edlund, Per, Norberg, Bengt, Wennstig, Anna-Karin, Lind, Pehr, Hauser, Nik, Tausch, Christoph, Camci, Celalettin, Arpaci, Fikret, Abali, Huseyin, Uslu, Ruchan, Tahir, Saad, Wheatley, Duncan, Chan, Stephen, Barrett-Lee, Peter, McAdam, Karen, Simcock, Richard, Burcombe, Russell, El-Maraghi, Robert, Califaretti, Nadia, Spadafora, Silvana, Sehdev, Sandeep, Sami, Amer, Verma, Sunil

Volltext

1st International consensus guidelines for advanced breast cancer (ABC 1) von Cardoso, F, Costa, A, Norton, L, Cameron, D, Cufer, T, Fallowfield, L, Francis, P, Gligorov, J, Kyriakides, S, Lin, N, Pagani, O, Senkus, E, Thomssen, C, Aapro, M, Bergh, J, Di Leo, A, El Saghir, N, Ganz, P.A, Gelmon, K, Goldhirsch, A, Harbeck, N, Houssami, N, Hudis, C, Kaufman, B, Leadbeater, M, Mayer, M, Rodger, A, Rugo, H, Sacchini, V, Sledge, G, van’t Veer, L, Viale, G, Krop, I, Winer, E

Volltext

Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program von Bello Roufai, D., Gonçalves, A., De La Motte Rouge, T., Akla, S., Blonz, C., Grenier, J., Gligorov, J., Saghatchian, M., Bailleux, C., Simon, H., Desmoulins, I., Tharin, Z., Renaud, E., Bertho, M., Benderra, M-A, Delaloge, S., Robert, L., Cottu, P., Pierga, J. Y., Loirat, D., Bertucci, A., Renouf, B., Bidard, F. C., Lerebours, F.

Volltext

Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologi... von Nabholtz, J.M., Abrial, C., Mouret-Reynier, M.A., Dauplat, M.M., Weber, B., Gligorov, J., Forest, A.M., Tredan, O., Vanlemmens, L., Petit, T., Guiu, S., Van Praagh, I., Jouannaud, C., Dubray-Longeras, P., Tubiana-Mathieu, N., Benmammar, K.E., Kullab, S., Bahadoor, M.R.K., Radosevic-Robin, N., Kwiatkowski, F., Desrichard, A., Cayre, A., Uhrhammer, N., Chalabi, N., Chollet, P., Penault-Llorca, F.

Volltext

Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients von Palich, R., Veyri, M., Marot, S., Vozy, A., Gligorov, J., Maingon, P., Marcelin, A.-G., Spano, J.-P.

Volltext

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cance... von Vrdoljak, E., Marschner, N., Zielinski, C., Gligorov, J., Cortes, J., Puglisi, F., Aapro, M., Fallowfield, L., Fontana, A., Inbar, M., Kahan, Z., Welt, A., Lévy, C., Brain, E., Pivot, X., Putzu, C., González Martín, A., de Ducla, S., Easton, V., von Minckwitz, G.

Volltext

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer tr... von Gourgou-Bourgade, S., Cameron, D., Poortmans, P., Asselain, B., Azria, D., Cardoso, F., A'Hern, R., Bliss, J., Bogaerts, J., Bonnefoi, H., Brain, E., Cardoso, M.J., Chibaudel, B., Coleman, R., Cufer, T., Dal Lago, L., Dalenc, F., De Azambuja, E., Debled, M., Delaloge, S., Filleron, T., Gligorov, J., Gutowski, M., Jacot, W., Kirkove, C., MacGrogan, G., Michiels, S., Negreiros, I., Offersen, B.V., Penault Llorca, F., Pruneri, G., Roche, H., Russell, N.S., Schmitt, F., Servent, V., Thürlimann, B., Untch, M., van der Hage, J.A., van Tienhoven, G., Wildiers, H., Yarnold, J., Bonnetain, F., Mathoulin-Pélissier, S., Bellera, C., Dabakuyo-Yonli, T.S.

Volltext